

Special Issue

Liver Cancer Heterogeneity in the Era of Single-Cell and Spatial Multiomics

Message from the Guest Editors

Liver cancers, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), remain among the most lethal malignancies worldwide, driven in part by their profound heterogeneity at the genetic, cellular, and microenvironmental levels. Traditional bulk profiling approaches have failed to capture the complexity of tumor subtypes, immune landscapes, and stromal interactions that define patient outcomes and therapeutic responses. This Special Issue aims to highlight recent advances in resolving liver cancer heterogeneity using high-dimensional technologies, including single-cell RNA sequencing, spatial transcriptomics, multiplexed imaging, and integrated multiomics approaches. We welcome original research papers and comprehensive reviews that explore cellular ecosystems of liver tumors and dissect intercellular signaling networks involved in immune evasion, fibrosis, and therapy resistance.

Guest Editors

Prof. Dr. Veronika Lukacs-Kornek

Institute of Experimental Immunology, University Bonn, Venusberg Campus 1, 53127 Bonn, Germany

Prof. Dr. Ralf Weiskirchen

Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, D-52074 Aachen, Germany

Deadline for manuscript submissions

31 July 2026



Livers

an Open Access Journal
by MDPI

Impact Factor 2.4
CiteScore 3.2



mdpi.com/si/246284

Livers

Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
livers@mdpi.com

[mdpi.com/journal/
livers](https://mdpi.com/journal/livers)





Livers

an Open Access Journal
by MDPI

Impact Factor 2.4
CiteScore 3.2



[mdpi.com/journal/
livers](https://mdpi.com/journal/livers)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Hartmut W. Jaeschke

Department of Pharmacology, Toxicology & Therapeutics, University of
Kansas Medical Center, Kansas City, KS 66160, USA

Author Benefits

High Visibility:

indexed within ESCI (Web of Science), Scopus, EBSCO,
and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is
provided to authors approximately 27 days after
submission; acceptance to publication is undertaken in 6.7
days (median values for papers published in this journal in
the second half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and
reviewer names published annually in the journal.